CD40 and neoplasm: In typical cases, siRNA delivery systems based on polymeric nanocarriers have demonstrated the ability to efficiently downregulate immune-related genes, such as targeting the CD40 gene in mouse models, significantly inhibiting the activation of macrophages and dendritic cells, thereby enhancing anti-tumor effects [110].